Biosimilar Competition Does Not Reduce Patient Out-of-Pocket Costs for Biologic Drugs

A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States. The research,…

Source


Comments are closed.

Biotechblog